This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To date, intravenous alteplase remains the only FDA-approved pharmacologic agent for the treatment of acute ischemic stroke. Among the contraindications to systemic thrombolysis with alteplase is therapeutic anticoagulation (or the use of warfarin with an INR >1.7), but not combination antiplatelet therapy. The most feared complication of treatment, symptomatic intracranial hemorrhage (sICH), may be more common in patients on dual antiplatelet pretreatment (DAPP) as shown in several studies and one previous meta-analysis. However, these data have not been consistently replicated. In their updated meta-analysis of 9 studies, including one randomized controlled clinical trial, 2 prospective registries, and 6 retrospective registries, Dr. Malhotra et al. observed that DAPP was associated with a two-fold higher odds of sICH in unadjusted regression (OR 2.26, 95% CI 1.39–3.67). This negative effect remained despite the use of varying definitions of sICH (SITS-MOST, ECASS II, and National Institute of Neurological Disorders and Stroke). However, after adjustment for confounders, the relationship no longer achieved statistical significance (ORadj 2.03, 95% CI 0.75–5.52, p = 0.16). Drs. Xu and Hu believed the analysis may have been confounded by overlapping patients between some of the included studies in this meta-analysis. Drs. Katsanos and Tsivgoulis confirmed—and we have independently verified—that there are no overlapping patients in this meta-analysis. Furthermore, the authors report the prospective TRISP registry corroborate the lack of a statistically significant, independent relationship between DAPP and sICH after thrombolysis (ORadj 1.29, 95% CI 0.82–2.05, p = 0.27). Although this information may provide us with greater reassurance regarding the safety of intravenous alteplase in patients on DAPP, these data highlight the importance of a priori significance thresholds. We believe readers should not be discouraged from using this FDA-approved acute treatment in patients prescribed DAPP but that does not mean one should not be cautious with it.
To date, intravenous alteplase remains the only FDA-approved pharmacologic agent for the treatment of acute ischemic stroke. Among the contraindications to systemic thrombolysis with alteplase is therapeutic anticoagulation (or the use of warfarin with an INR >1.7), but not combination antiplatelet therapy. The most feared complication of treatment, symptomatic intracranial hemorrhage (sICH), may be more common in patients on dual antiplatelet pretreatment (DAPP) as shown in several studies and one previous meta-analysis. However, these data have not been consistently replicated. In their updated meta-analysis of 9 studies, including one randomized controlled clinical trial, 2 prospective registries, and 6 retrospective registries, Dr. Malhotra et al. observed that DAPP was associated with a two-fold higher odds of sICH in unadjusted regression (OR 2.26, 95% CI 1.39–3.67). This negative effect remained despite the use of varying definitions of sICH (SITS-MOST, ECASS II, and National Institute of Neurological Disorders and Stroke). However, after adjustment for confounders, the relationship no longer achieved statistical significance (ORadj 2.03, 95% CI 0.75–5.52, p = 0.16). Drs. Xu and Hu believed the analysis may have been confounded by overlapping patients between some of the included studies in this meta-analysis. Drs. Katsanos and Tsivgoulis confirmed—and we have independently verified—that there are no overlapping patients in this meta-analysis. Furthermore, the authors report the prospective TRISP registry corroborate the lack of a statistically significant, independent relationship between DAPP and sICH after thrombolysis (ORadj 1.29, 95% CI 0.82–2.05, p = 0.27). Although this information may provide us with greater reassurance regarding the safety of intravenous alteplase in patients on DAPP, these data highlight the importance of a priori significance thresholds. We believe readers should not be discouraged from using this FDA-approved acute treatment in patients prescribed DAPP but that does not mean one should not be cautious with it.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2021 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
Advances in thrombolytics for treatment of acute ischemic stroke
Lp-PLA2 and dual antiplatelet agents in intracranial arterial stenosis
Dual antiplatelet therapy pretreatment in IV thrombolysis for acute ischemic stroke
High-sensitive C-reactive protein and dual antiplatelet in intracranial arterial stenosis